Pharmacogenetics of β2 adrenergic receptor gene polymorphisms, long-acting β-agonists and asthma

Clinical and Experimental Allergy

Volumn 41, Issue 3, 2011, Pages 312-326

  Chung, L P ^a,b   Waterer, G ^b,c   Thompson, P J ^a,b,d  

^a Centre for Asthma   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FENOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; MONTELUKAST; SALBUTAMOL; SALMETEROL;

3' UNTRANSLATED REGION; ASTHMA; CLINICAL TRIAL; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; NUCLEOTIDE REPEAT; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-AGONISTS; ASTHMA; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2;

EID: 79551619357     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03696.x     Document Type: Review

References (91)

1. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56:1054-70.
2. Evans WE, McLeod HL. Pharmacogenomics - drug deposition, drug targets, and side effects. N Engl J Med 2003; 348:538-49.
3. Weiss ST, Litonjua AA, Lange C et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J 2006; 6:311-26.
4. GINA. National Heart Lung and Blood Institute; National Institute of Health. Global strategy for asthma management and prevention: Global initiative for asthma (GINA). GINA, 2008. Available at (Accessed 15 March 2010).
5. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170:836-44.
6. Gibson PG, Powell H, Ducharme F. Long-acting beta2-agonists as in an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev 2005, Art No.: CD005076; DOI: DOI: 10.1002/14651858.CD005076.
7. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The optima randomized trial. Am J Respir Crit Care Med 2001; 164:1392-7.
8. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-11.
9. Grainger J, Woodman K, Pearce N et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991; 46:105-11.
10. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of New Zealand asthma mortality epidemic. Lancet 1995; 345:41-4.
11. Pearce N, Burgess C, Crane J et al. Fenoterol, asthma deaths, and asthma severity. Chest 1997; 112:1148-50.
12. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336:1391-6.
13. Suissa S, Ernst P, Boivin JF et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149:604-10.
14. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-7.
15. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
16. Panebra A, Wang WC, Malone MM et al. Common ADRβ2 haplotypes derived from 26 polymorphic sites direct β2-adrenergic receptor expression and regulation phenotypes. PLoS One 2010; 5:e11819.
17. Aziz I, McFarlane LC, Lipworth BJ. Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor-regulation and bronchodilatation. Eur J Clin Pharmacol 1999; 55:431-6.
18. Cho SH, Oh SY, Bahn JW et al. Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene. Clin Exp Allergy 2005; 35:1162-7.
19. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-12.
20. Israel E, Drazen JM, Liggett SB et al. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001; 124:183-6.
21. Kotani Y, Nishimura Y, Maeda H, Yokoyama M. Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J Asthma 1999; 36:583-90.
22. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65:519-25.
23. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-8.
24. Silverman EK, Kwiatkowski DJ, Sylvia JS et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 2003; 112:870-6.
25. Tan S, Hall IP, Dewar J et al. Association between beta 2 adrenoceptor polymorphisms and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350:995-9.
26. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55:762-7.
27. Wechsler ME, Lehman E, Lazarus SC et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-26.
28. Giembycz MA, Newton R. Beyond the dogma: novel {beta}2-adrenoceptor signalling in the airways. Eur Respir J 2006; 27:1286-306.
29. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117:18-24.
30. Koite K, Yamashita Y, Horionouchi T, Yamaki F, Tanaka Y. cAMP-independent mechanism is significantly involved in b2-adrenoceptor-mediated tracheal relaxation. Eur J Pharmacol 2004; 492:65-70.
31. Spicuzza L, Belvisi MG, Birrell MA, Barnes PJ, Hele HJ, Spicuzza L. Evidence that the anti-spasmogenic effect of the b-adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cycic amp-dependent protein kinase. Br J Pharmacol 2001; 133:1201-12.
32. Roth M, Johnson PRA, Rüdiger JJ et al. Interaction between glucocorticoids and [beta]2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360:1293-9.
33. Johnson M. The beta -adrenoceptor. Am J Respir Crit Care Med 1998; 158:S146-53.
34. Williams BR, Barber R, Clark RB. Kinetic analysis of agonist-induced downregulation of the beta(2)-adrenergic receptor in beas-2b cells reveals high- and low-affinity components. Mol Pharmacol 2000; 58:421-30.
35. Moore RH, Tuffaha A, Millman EE et al. Agonist-induced sorting of human beta2-adrenergic receptors to lysosomes during downregulation. J Cell Sci 1999; 112:329-38.
36. Hadcock JR, Malbon CC. Downregulation of b-adrenergic receptors: agonist-induced reduction in receptor mrna levels. Proc Natl Acad Sci USA 1988; 85:5021-5.
37. Kobilka BK, Frielle T, Dohlman HG et al. Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions. J Biol Chem 1987; 262:7321-7.
38. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8:334-9.
39. Hawkins GA, Tantisira K, Meyers DA et al. Sequence, haplotype, and association analysis of adrbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006; 174:1101-9.
40. Weir TD, Mallek NOA, Sandford AJ et al. Beta 2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998; 158:787-91.
41. Xie HG, Stein CM, Kim RB et al. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 1999; 9:511-6.
42. Brodde OE, Leineweber K. B2-adrenoceptor gene polymorphisms. Pharmacogenetics Genomics 2005; 15:267-75.
43. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43:381-411.
44. Holloway JW, Dunbar PR, Riley GA et al. Association of beta2-adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy 2000; 30:1097-103.
45. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998; 102:1927-32.
46. Scott MG, Swan C, Wheatly AP, Hall IP. Identification of novel polymorphisms within the promoter region of the human β2 adrenergic receptor gene. Br J Pharmacol 1999; 126:841-4.
47. Westland R, van Veen A, Jansen HM, Jonkers RE, Wierenga EA. Limited impact of multiple 5' single-nucleotide polymorphisms on the transcriptional control of the human beta 2-adrenoceptor gene. Immunogenetics 2004; 56:625-30.
48. Drysdale CM, McGraw DW, Stack CB et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97:10483-8.
49. Green SA, Turki J, Hall IP, Liggett SB. Implications of genetic variability of human beta 2-adrenergic receptor structure. Pulm Pharmacol 1995; 8:1-10.
50. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33:9414-9.
51. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268:23116-21.
52. Moore PE, Laporte JD, Abraham JH et al. Polymorphism of the beta(2)-adrenergic receptor gene and desensitization in human airway smooth muscle. Am J Respir Crit Care Med 2000; 162:2117-24.
53. Leineweber K, Tenderich G, Wolf C et al. Is there a role of the thr164ile-[beta]2-adrenoceptor polymorphism for the outcome of chronic heart failure? Basic Res Cardiol 2006; 101:479-84.
54. Liggett S, Wagoner L, Craft L et al. The ile164 beta2-adrenergic receptor polymorphisms adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102:1534-9.
55. Wagoner L, Craft L, Singh B et al. Polymorphisms of the beta2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86:834-40.
56. Strader CD, Candelore MR, Hill WS, Sigal IS, Dixon RA. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 1989; 264:13572-8.
57. Barbato E, Penicka M, Delrue L et al. Thr164ile polymorphism of the beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy. Heart 2007; 93:856-61.
58. Brodde O, Buscher R, Tellkamp R, Radke J, Dhein S, Insel P. Blunted cardiac responses to receptor activation in subjects with thr164ile beta2-adrenoceptors. Circulation 2001; 103:1048-50.
59. Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 2001; 421:141-17.
60. Panebra A, Schwarb MR, Swift SM et al. Variable-length poly-c tract polymorphisms of the beta2-adrenergic receptor 3'-utr alter expression and agonist regulation. Am J Physiol Lung Cell Mol Physiol 2008; 294:190-5.
61. Taylor DR, Epton MJ, Kennedy MA et al. Bronchodilator response in relation to {beta}2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 2005; 172:700-3.
62. Choudhry S, Ung N, Avila PC et al. Pharmacogenetic differences in response to albuterol between puerto ricans and mexicans with asthma. Am J Respir Crit Care Med 2005; 171:563-70.
63. Carter-Pokras OD, Gergen PJ. Reported asthma among Puerto Rican, Mexican-American, and Cuban children: 1982 through 1984. Am J Public Health 1993; 83:580-2.
64. Homa DM, Mannino DM, Lara M. Asthma mortality in U.S. Hispanics of Mexican, Puerto Rican, and Cuban heritage, 1990-1995. Am J Respir Crit Care Med 2000; 161:504-9.
65. Drazen JM, Israel E, Boushey HA et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996; 335:841-7.
66. Broadley KJ. [beta]-adrenoceptor responses of the airways: for better or worse? Eur J Pharmacol 2006; 533:15-27.
67. Sears M, Taylor D. The beta2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf 1994; 11:259-83.
68. Loza M, Peters S, Foster S, Khan I, Penn R. Beta 2 Agonist enhances type 2 T-cell survival and accumulation. J Allergy Clin Immunol 2007; 119:235-44.
69. Nguyen LP, Lin R, Parra S et al. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci USA 2009; 106:2435-40.
70. Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 1998; 11:589-93.
71. Liggett SB. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000; 61:167-73.
72. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006; 61:940-4.
73. Lazarus SC, Boushey HA, Fahy JV et al. Long-acting {beta}2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285:2583-93.
74. Lemanske RF, Sorkness CA Jr, Mauger EA et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285:2594-603.
75. Bleecker ER, Yancey SW, Baitinger LA et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809-16.
76. Anderson W, Bleecker ER, Nelson H et al. Lack of effect of promoter, coding and 3' polymorphisms of the [beta]2-adrenergic receptor (ADRB2) on the clinical response to salmeterol alone or with fluticasone propionate in subjects with asthma. J Allergy Clin Immunol 2008; 121:S143.
77. Bleecker ER, Nelson H, Corren J et al. Arg16gly polymorphism of the [beta]2-adrenergic receptor gene does not modulate clinical response to salmeterol in subjects with asthma. J Allergy Clin Immunol 2008; 121:S143.
78. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of adrb2 polymorphisms on response to long-acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370:2118-25.
79. Wechsler ME, Kunselman SJ, Chinchilli VM et al. Effect of [beta]2-adrenergic receptor polymorphism on response to long-acting [beta]2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374:1754-64.
80. Bleecker ER, Nelson HS, Kraft M et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181:676-87.
81. January B, Seibod A, Allal C et al. Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2 adrenoceptor. Br J Clin Pharmacol 1998; 123:701-11.
82. Moore RH, Millman EE, Godines V et al. Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. Am J Respir Cell Mol Biol 2007; 36:254-61.
83. Lee DKC, Currie GP, Hal IP, Lima JJ, Lipworth BJ. The arginine-16 β2-adrenergic polymorphism predisposes to bronchoprotective subsensitivity in patients with formoterol and sameterol. Br J Clin Pharmacol 2003; 57:68-75.
84. Tellería JJ, Blanco-Quirós A, Muntión S et al. Tachyphylaxis to [beta]2-agonists in Spanish asthmatic patients could be modulated by [beta]2-adrenoceptor gene polymorphisms. Respir Med 2006; 100:1072-8.
85. Carroll C, Stoltz P, Schramm C, Zucker A. Beta2 adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest 2009; 135:1186-92.
86. Martin AC, Zhang G, Rueter K et al. Beta2-adrenoceptor polymorphisms predict response to beta2-agonists in children with acute asthma. J Asthma 2008; 45:383-8.
87. Mathews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004; 113:1100-8.
88. Wang WCH, Mihlbachler KA, Bleecker ER, Weiss ST, Liggett SB. A polymorphism of g-protein coupled receptor kinase5 alters agonist-promoted desensitization of [beta]2-adrenergic receptors. Pharmacogenetics Genomics 2008; 18:729-32.
89. Small KM, Brown KM, Theiss CT et al. An ile to met polymorphism in the catalytic domain of adenylyl cylase type 9 confers reduced beta 2 adrenergic receptor stimulation. Pharmacogenetics 2003; 13:535-41.
90. Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between {beta}-agonist and corticosteroid pathways. Hum Mol Genet 2005; 14:1671-7.
91. Ortega VE, Hawkins GA, Peters SP, Bleecker ER. Pharmacogenetics of the beta 2-adrenergic receptor gene. Immunol Allergy Clin North Am 2007; 27:665-84.